Matthieu Masureel

Matthieu Masureel

Auto-generated profile, based on publicly available information

Matthieu Masureel

Department of Structural Biology, Genentech Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SNSigrid Noreng
Sigrid Noreng
NONaruhisa Ota
Naruhisa Ota
YSYonglian Sun
Yonglian Sun
HHHoangdung Ho
Hoangdung Ho
MJMatthew Johnson
Matthew Johnson
JKJames T. Koerber
James T. Koerber
NOX2 is the prototypical member of the NADPH oxidase NOX superfamily and produces superoxide (O2•−), a key reactive oxygen species (ROS) that is essential in innate and adaptive immunity. Mutations that lead to deficiency in NOX2 activity correlate with increased susceptibility to bacterial and fungal infections, resulting in chronic granulomatous disease. The core of NOX2 is formed by a heterodimeric transmembrane complex composed of NOX2 (formerly gp91) and p22, but a detailed description of its structural architecture is lacking. Here, we present the structure of the human NOX2 core complex bound to a selective anti-NOX2 antibody fragment. The core complex reveals an intricate extracellular topology of NOX2, a four-transmembrane fold of the p22 subunit, and an extensive transmembrane interface which provides insights into NOX2 assembly and activation. Functional assays uncover an inhibitory activity of the 7G5 antibody mediated by internalization-dependent and internalization-independent mechanisms. Overall, our results provide insights into the NOX2 core complex architecture, disease-causing mutations, and potential avenues for selective NOX2 pharmacological modulation.

20 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSM. J. Strohman
M. J. Strohman
SMS. Maeda
S. Maeda
DHDaniel Hilger
Daniel Hilger
MMM. Masureel
M. Masureel
YDY. Du
Y. Du
BKB. K. Kobilka
B. K. Kobilka
The β2 adrenergic receptor (β2AR) signals through both Gs and Gi in cardiac myocytes, and the Gi pathway counteracts the Gs pathway. However, Gi coupling is much less efficient than Gs coupling in most cell-based and biochemical assays, making it difficult to study β2AR−Gi interactions. Here we investigate the role of phospholipid composition on Gs and Gi coupling. While negatively charged phospholipids are known to enhance agonist affinity and stabilize an active state of the β2AR, we find that they impair coupling to Gi3 and facilitate coupling to Gs. Positively charged Ca2+ and Mg2+, known to interact with the negative charge on phospholipids, facilitates Gi3 coupling. Mutational analysis suggests that Ca2+ coordinates an interaction between phospholipid and the negatively charged EDGE motif on the amino terminal helix of Gi3. Taken together, our observations suggest that local membrane charge modulates the interaction between β2AR and competing G protein subtypes.

30 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMichael T. Lerch
Michael T. Lerch
RMRachel A. Matt
Rachel A. Matt
MMMatthieu Masureel
Matthieu Masureel
MEMatthias Elgeti
Matthias Elgeti
KKKaavya Krishna Kumar
Kaavya Krishna Kumar
WHWayne Hubbell
Wayne Hubbell
Significance: The molecular origin of basal activity in G protein coupled receptors and its suppression by inverse agonists are poorly understood. Here we employ pressure-resolved DEER spectroscopy to explore the structural origin of basal activity and the mechanism of inverse agonism in the β 2 adrenergic receptor. Collectively, the results support a conformational selection model wherein basal activity is due to a preexisting equilibrium between inactive and active conformations in the unliganded receptor, and inverse agonists stabilize the inactive conformation. Furthermore, the results illustrate the importance of rare states in molecular mechanisms of protein function and the capability of pressure-resolved DEER for revealing structural features of sparsely populated conformations of membrane proteins and for determining their thermodynamic properties.

16 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLuis F. Schachner
Luis F. Schachner
CMChristopher Mullen
Christopher Mullen
WPWilson Phung
Wilson Phung
JHJoshua D. Hinkle
Joshua D. Hinkle
MBMichelle Irwin Beardsley
Michelle Irwin Beardsley
WSWendy Sandoval
Wendy Sandoval
The heterogeneity inherent in today’s biotherapeutics, especially as a result of heavy glycosylation, can affect a molecule’s safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins or other heterogeneous biotherapeutics. Here, we present an approach to the molecular assessment of biotherapeutics that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact heterogeneous and/or glycosylated proteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment. For glycoproteins in particular, the method may offer insights into glycan composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.

1 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDawei Sun
Dawei Sun
YSYonglian Sun
Yonglian Sun
EJEric Janezic
Eric Janezic
TZTricia Zhou
Tricia Zhou
MJMatthew Johnson
Matthew Johnson
MMMatthieu Masureel
Matthieu Masureel
The C-C motif chemokine receptor 8 (CCR8) is a class A G-protein coupled receptor that has emerged as a promising therapeutic target in cancer. Targeting CCR8 with an antibody has appeared to be an attractive therapeutic approach, but the molecular basis for chemokine-mediated activation and antibody-mediated inhibition of CCR8 are not fully elucidated. Here, we obtain an antagonist antibody against human CCR8 and determine structures of CCR8 in complex with either the antibody or the endogenous agonist ligand CCL1. Our studies reveal characteristic antibody features allowing recognition of the CCR8 extracellular loops and CCL1-CCR8 interaction modes that are distinct from other chemokine receptor - ligand pairs. Informed by these structural insights, we demonstrate that CCL1 follows a two-step, two-site binding sequence to CCR8 and that antibody-mediated inhibition of CCL1 signaling can occur by preventing the second binding event. Together, our results provide a detailed structural and mechanistic framework of CCR8 activation and inhibition that expands our molecular understanding of chemokine - receptor interactions and offers insight into the development of therapeutic antibodies targeting chemokine GPCRs.

15 July 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TBTravis Bainbridge
Travis Bainbridge
LWLifen Wang
Lifen Wang
MMMarina Moskalenko
Marina Moskalenko
RHRobert Herrera
Robert Herrera
MPMaciej T Paluch
Maciej T Paluch
BBBeyza Bulutoglu
Beyza Bulutoglu
Background: The pro-inflammatory cytokine, interleukin-18 (IL-18), plays an instrumental role in bolstering anti-tumor immunity. However, the therapeutic application of IL-18 has been limited due to its susceptibility to neutralization by IL-18 binding protein (IL-18BP), short in vivo half-life, and unfavorable physicochemical properties. Methods: In order to overcome the poor drug-like properties of IL-18, we installed an artificial disulfide bond, removed the native, unpaired cysteines, and fused the stabilized cytokine to an IgG Fc domain. The stability, potency, pharmacokinetic and pharmacodynamic properties as well as efficacy of disulfide-stabilized IL-18 Fc-fusion (dsIL-18-Fc) were assessed via in vitro and in vivo studies. Results: The stability and mammalian host cell production yields of dsIL-18-Fc were improved, compared to the wild-type (WT) cytokine, while maintaining its biological potency and interactions with IL-18 receptor α (IL-18Rα) and IL-18BP. Recombinant fusion of the cytokine to an IgG Fc domain provided extended half-life. Notably, despite maintaining sensitivity to IL-18BP, dsIL-18-Fc was effective at activating both T and natural killer (NK) cells, and elicited a strong anti-tumor response, either as a single agent, or in conjunction with anti-programmed cell death-ligand 1 (anti-PD-L1) therapy. Conclusions: We engineered IL-18 for reinforced stability, extended half-life, and improved manufacturability. The therapeutic benefit of dsIL-18-Fc, coupled with a more favorable manufacturability profile and enhanced drug-like properties, underscores the potential utility of this engineered cytokine in cancer immunotherapy.